Cat. No. | Product name | CAS No. |
DC8497 |
CC-223
Featured
CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM). |
1228013-30-6 |
DC7096 |
CC-401
Featured
CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. |
1438391-30-0 |
DC7978 |
Tucidinostat(Chidamide)
Featured
Chidamide is a class I HDAC inhibitor with IC50s of 95/160/67/733 nM for HDAC1/2/3/8; also inhibits HDAC10/11(IC50=78/432 nM); no inhibition on HDAC4/5/7/9/6(IC50>30 uM). |
743420-02-2 |
DC8116 |
Tosedostat (CHR2797)
Featured
CHR-2797 is an aminopeptidase inhibitor, with IC50 values of 100 nM for LAP3 (LAP), 150 nM for PSAP (PuSA) and 220 nM for CD13 (Aminopeptidase N). |
238750-77-1 |
DC10341 |
CHZ868
CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell. |
1895895-38-1 |
DC9799 |
CNDAC
Featured
CNDAC is the active component of sapacitabine. |
135598-68-4 |
DC5159 |
CP-868596 (Crenolanib)
Featured
Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB |
670220-88-9 |
DC7111 |
CX-4945 (Silmitasertib)
Featured
CX-4945 (Silmitasertib) is a potent and selective ATP-competitive small molecule protein kinase CK2 inhibitor with a Ki and an IC50 of 0.38 and 1 nM for recombinant human CK2α, respectively. |
1009820-21-6 |
DC7153 |
CX6258
Featured
CX-6258 is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity. |
1202916-90-2 |
DC5134 |
lexibulin (CYT997)
CYT997 is a potent microtubule polymerization inhibitor with IC50 of 10-100 nM in cancer cell lines. Phase 1/2. |
917111-44-5 |
DC4125 |
PHA-739358 (danusertib)
Featured
Danusertib (PHA-739358) is an Aurora inhibitor for Aurora A/B/C, Bcr-Abl, c-RET and FGFR with IC50 of 13 nM/79 nM/61 nM, 25 nM, 31 nM and 47 nM, respectively. |
827318-97-8 |
DC2100 |
Dasatinib (BMS-354825)
Featured
Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.5 nM and 79 nM, respectively. |
302962-49-8 |
DC5041 |
DCC-2036 (Rebastinib)
Featured
DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1/2. |
1020172-07-9 |
DC10413 |
DDP-38003 dihydrochloride
DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC50 of 84 nM. |
1831167-98-6 |
DC8481 |
Delanzomib(CEP-18770)
Featured
Delanzomib(CEP-18770) is a novel orally-active inhibitor of the chymotrypsin-like activity of the proteasome that down-modulates the nuclear factor-kappaB (NF-kappaB) activity. |
847499-27-8 |
DC7114 |
Dinaciclib (SCH727965)
Featured
Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively. |
779353-01-4 |
DC4157 |
Dovitinib (TKI258, CHIR258)
Featured
Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively. |
405169-16-6 |
DC10313 |
Dovitinib lactate
Dovitinib(CHIR-258; TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) with an IC50 of 5 nM. |
692737-80-7 |
DC11726 |
DS-3032b
Featured
DS-3032b is a potent, selective, orally available MDM2-p53 inhibitor with potential antineoplastic activity. |
1398568-47-2 |
DC9755 |
eFT508(Tomivosertib)
Featured
Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
1849590-01-7 |
DC5057 |
Enzastaurin (LY317615)
Featured
Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3. |
170364-57-5 |
DC7927 |
EPZ011989
Featured
EPZ011989 is a potent, orally-available EZH2 Inhibitor. |
1598383-40-4 |